Although initially developed as a brief dementia battery, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has not yet demonstrated its sensitivity, specificity, and positive and negative predictive powers in detecting cognitive impairment in patients with Alzheimer's disease (AD). Therefore, the current study examined the clinical utility of the RBANS by comparing two age-, education-, and gender-matched groups: patients with AD (n = 69) and comparators (n = 69). Significant differences (p < 0.001) were observed on the RBANS Total score, all 5 Indexes, and all 12 subtests, with patients performing worse than the comparison participants. An optimal balance between sensitivity and specificity on RBANS scores was obtained when cutoffs of one and one and a half standard deviations below the mean of the comparison sample were implemented. Areas under the Receiver Operating Characteristic curves for all RBANS Indexes were impressive though Immediate and Delayed Memory Indexes were excellent (0.96 and 0.98, respectively). Results suggest that RBANS scores yield excellent estimates of diagnostic accuracy and that the RBANS is a useful screening tool in detection of cognitive deficits associated with AD.
Introduction
Alzheimer's disease (AD) has been characterized as a primary progressive dementia with early deficits in learning and memory, orientation, and language (Eisdorfer & Cohen, 1980; Huff et al., 1987) . Numerous studies have identified and tracked the cognitive deficits associated with AD with either brief screening measures (e.g., Mini Mental Status Examination) (Han, Cole, Bellavance, McCusker, & Primeau, 2000) or more comprehensive neuropsychological batteries (Baudic et al., 2006; Germano & Kinsella, 2005; Laws, Adlington, Gale, Moreno-Martinez, & Sartori, 2007; Spaan, Raaijmakers, & Jonker, 2003) . As pharmacological interventions for AD continue to expand (e.g., cholinesterase inhibitors, glutamate antagonists, statins), there is an increasing need for measures that are both brief and sensitive in identifying appropriate patients with the earliest cognitive deficits associated with AD for clinical trials. These screening measures need to be relatively brief, yet comprehensive enough to provide adequate diagnostic accuracy (e.g., sensitivity, specificity) (Kraemer, 1992; O'Bryant & Lucas, 2006) .
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (Randolph, 1998 ) is one recently developed screening battery that might prove useful in detecting AD for clinical trial purposes. Although the RBANS has been well validated in community-dwelling "normal" elderly samples (Duff et al., , 2004 (Duff et al., , 2005 , adequate information regarding the diagnostic accuracy of this screening instrument in detecting cognitive impairment associated with AD is still lacking. Randolph, Tierney, Mohr, and Chase (1998) reported on a small sample of patients with AD and observed that they performed more poorly than elderly controls on four of the five RBANS Indexes, with scores on only the Visuospatial Constructional Index being comparable between the two groups. Similar findings are reported in the test's manual (Randolph, 1998) , which describes poorer performances on the Immediate and Delayed Memory and Language Indexes in patients with AD than healthy controls. While it is clear from these studies that AD patients perform more poorly than non-AD controls, a formal examination of RBANS diagnostic accuracy estimates has yet to be completed. Research is also lacking on the usefulness of the individual RBANS subtests in addition to the Total Scale score and the five Indexes.
In order for any test (medical, neuropsychological, or other) to be clinically useful, its psychometric properties must be explored and shown to be adequate. Following the establishment of reliability and validity -both of which are adequate for the RBANS in AD samples Silva, Humphreys, Dempsey, O'Bryant, & Sutker, 2006 ) -assessment of the diagnostic accuracy for the instrument is considered. Diagnostic accuracy, according to the Standards for Reporting of Diagnostic Accuracy (STARD) work group (Bossuyt et al., 2003) , must compare results from a test (e.g., RBANS) to those obtained using a reference standard (e.g., consensus-based diagnosis). The "amount of agreement between the results from the index test and those from the reference standard" (p. 8) indicates the accuracy of that test. Estimates of diagnostic accuracy cited by this group include sensitivity, specificity, likelihood ratios, diagnostic odds ratios, and areas under Receiver Operating Characteristic (ROC) curves. While each estimate of diagnostic accuracy has its strengths and weaknesses (for full review see Kraemer, 1992) , ROC curves have the advantage of providing a single estimate of diagnostic accuracy that does not require that ordinal and continuous test scores be simplified and therefore allow for the full range of cognitive scores to be examined (Lett, Hanley, & Smith, 1995) . The areas under a curve (AUC) of a ROC represents the probability that normal and abnormal test scores will be correctly classified as their disease (or non-disease) state (e.g., AD or non-AD control) (Hanley & McNeil, 1982) and is reflected as a single percentage.
The purpose of the current study was to evaluate the diagnostic accuracy of the RBANS in detecting cognitive deficits associated with AD by comparing a group of clinically diagnosed patients with AD to a sample of age-, education-, and gender-matched non-AD comparison participants. It was hypothesized that the AD patients would perform more poorly than matched peers on most RBANS Index and subtest scores. Based on past research , only the Visuospatial Constructional Index was expected to be comparable between these two groups. To provide information necessary for advancing clinical trials in AD, sensitivity, specificity, odds ratios, and ROC data were calculated using various cutoff points (1, 1.5, and 2 standard deviations below the mean) for RBANS scores. For example, 1 standard deviation below the mean can represent the lower end of normal (16th percentile); 1.5 standard deviations below the mean has been frequently cited in literature identifying impairment in Mild Cognitive Impairment (Petersen et al., 2001) ; and 2 standard deviations below the mean appears to clearly fall into the impaired range (2nd percentile).
Methods

Participants
Sixty-nine patients diagnosed with AD were selected for the current study from a memory disorder clinic at a southern medical center. Patients were assigned diagnoses of AD by a consensus panel including neuropsychologists and neurologists using NINCDS-ADRDA criteria (McKhann et al., 1984) following a clinical examination. Demographic data on these patients is presented in Table 1 . Sixty-nine comparison patients were selected from the larger pool of participants in the OKLAHOMA study . The OKLAHOMA study recruited community-dwelling elders who regularly attend primary care clinics at a south central medical center, and these elders were followed in a longitudinal study of health outcomes. We refrain from calling these participants "healthy controls" for the following reasons. First, they are not completely healthy, and they suffer from many illnesses associated with aging (e.g., diabetes, hypertension, cancer). Second, these elders were not formally screened for dementia, although OKLAHOMA study personnel did exclude individuals that were too confused to provide informed consent. Third, we acknowledge that this comparison group could include individuals with dementia or other types of milder cognitive impairments; however, their cognitive data seem to reflect "normal" performances (e.g., see Table 1 , mean RBANS Total score = 99.4).
Procedures
All procedures were approved by the Institutional Review Boards at the appropriate institutions before any data was collected. Each participant signed written informed consent for his/her assessment data to be used for research purposes. For AD patients who were incapable of providing consent on his/her own behalf, a legal representative provided written informed consent and the patient provided assent.
Each patient with AD was matched to a comparison patient on variables shown to affect cognitive functioning (i.e., age, education, and gender) (Bland & Altman, 1994; Kazdin, 1998) . In matching patients, age was considered first, followed by education, followed by gender. As can be seen in Table 1 , matching was not exact, but no significant differences were present between the two groups on age, education, or gender.
All AD patients completed a neurological examination and neuropsychological evaluation as part of a clinic visit. The neuropsychological battery included the Mini Mental Status Examination (Folstein, Folstein, & McHugh, 1975) , Clinical Dementia Rating (CDR) scale (Morris, 1997), Wechsler Memory Scale-III (Wechsler, 1997b) , Wechsler Adult Intelligence Scale-III (Wechsler, 1997a) , and the RBANS (Form A), as well as other standard neuropsychological measures. Scores from these cognitive measures, along with clinical information about signs, symptoms, onset, and course, were considered by the consensus panel when assigning diagnoses. For the comparison patients, the RBANS (Form A) was the only measure of cognition administered as part of the OKLAHOMA study.
Measures
The RBANS (Randolph, 1998 ) is a brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory. It consists of 12 subtests, which yield 5 Index scores and a Total Scale score. Normative information from the manual, which is used to calculate the Index and Total scores, is based on 540 healthy adults who ranged in age from 20 to 89 years old. Index scores have a mean of 100 and standard deviation of 15. All subtests were administered and scored as defined in the manual, with the exception of the Figure Copy and Figure Recall , which are more thoroughly described elsewhere (Duff et al., 2007) . Briefly, the modified scoring criteria of the figure followed less stringent adherence to the manual's scoring criteria. Examples of these modifications include less exact measurements, emphasizing the majority of correct elements, and discouraging the use of a ruler or protractor for measuring elements. The figures of both the AD and comparison patients were scored using these same modified scoring criteria. All scores were normed using the data provided in the test manual (Randolph, 1998) .
Statistical analyses
Independent t-tests and chi-square analyses were calculated to compare the two groups on age, education, and gender. An ANOVA was used to compare the two groups on the RBANS Total Scale score; two MANOVAs were conducted to compare scores from the two groups on the 5 Indexes and 12 subtests of the RBANS. An alpha level of 0.05 was maintained to test the three primary analyses. Sensitivity, specificity, and odds ratios at various cutoff points were calculated as outlined by Kraemer (1992) ; diagnostic accuracy was estimated using ROC curves and calculation of AUC via non-parametric analyses using SPSS 14.0. Positive and negative predictive powers were also calculated.
Results
Patients diagnosed with AD and the comparison patients were comparable in age (p = 0.89; age range for both groups 66-89 years), education (p = 0.36), and gender (p = 0.72). Descriptive statistics are presented in Table 1 . Despite being closely matched on these variables, there were significant differences between the groups on the RBANS Total Scale Table 1 , and reflected in subsequent univariate tests, the patients with AD fell below the comparison patients on all measures. Sensitivity, specificity, and odds ratios at cutoff scores of −1, −1.5, and −2 standard deviations of the non-AD comparison group for all Index and individual subtest scores are presented in Table 2 . Additionally, positive and negative predictive powers for these same cutoff scores are presented in Table 3 . These cutoff scores would be equivalent to standard scores (i.e., M = 100, S.D. = 15) of 85, 77, and 70, respectively. ROC curves for the five Indexes and the Total Scale score are presented in Fig. 1 
Discussion
Present findings support the clinical utility of the RBANS in detecting the cognitive deficits associated with AD. Compared to age-, education-, and gender-matched peers, patients with AD performed significantly lower on all Indexes and subtests of this screening battery. These results are generally consistent with the limited published literature on the RBANS in patients with this dementing illness , in that significant deficits were observed for AD patients on Immediate and Delayed Memory, Language, and Attention Indexes. The current study also found significant declines on the Visuospatial Constructional Index, which was not observed in the prior work. This discrepancy between the current results and those previously reported could be attributed to sample differences because AD patients in the current study appear to be more impaired than those investigated by Randolph et al. (mean Total Scale score: 64.5 vs. 81.4) . Additionally, the present AD sample was larger, older, and had more women than the sample studied by Randolph et al. Data included in the RBANS manual (Randolph, 1998) , based on a larger sample, showed a pattern of cognitive impairments that was consistent with the current results. Consistent with other literature on AD, significant differences were observed between patients diagnosed with AD and comparison elders on indices of immediate and delayed memory (Knopman, 2003) , and AUC was most impressive for these two RBANS Indexes. The remaining three Indexes (Attention, Language, Visuospatial Constructional) were equally impaired in AD patients, with small to moderate effect sizes, and all three demonstrated good diagnostic accuracy as estimated by AUC. Overall, results support the use of all five Indexes of the RBANS in identifying cognitive impairments in patients with AD.
Prior studies with the RBANS in AD have not reported on the individual subtests, which might provide more clinical information than the Index scores. Using effect sizes (i.e., partial eta 2 ), the largest deficits occurred on learning and memory subtests (List Recall, List Recognition, Story Recall, Figure Recall) . As expected, Semantic Fluency was another clinically relevant subtest, which supports other cognitive findings associated with AD (Binetti et al., 1996; Cooper et al., 2001; Guarch, Marcos, Salamero, & Blesa, 2004) . Picture Naming was the subtest with the lowest effect size. As only one-half point separated the raw scores for the two groups on this subtest, the clinical utility of this 10-item subtest in AD is questionable, perhaps attributed to a ceiling effect. A ceiling effect would also explain its poor discriminability, and such findings support the use of longer versions of confrontational naming tests, such as the Boston Naming Test (Kaplan, Goodglass, & Weintraub, 1983) .
In view of the lower RBANS scores of patients diagnosed with AD, the RBANS has utility in the diagnosis of AD and in the planning and evaluating clinical trials. Sensitivity, specificity, ROC curves, and AUC estimates are routinely used in medicine to evaluate clinical measures (Nash et al., 2006; Schmidt et al., 2006; Stephan et al., 2006) . Scanning Table 2 , a cutoff of one standard deviation below the mean is best at discriminating patients with AD from comparison patients on most of the RBANS subtests and Indexes. The Delayed Memory Index and its subtests, however, provide the most optimal balance between sensitivity and specificity when a one and a half standard deviations cutoff is implemented. This latter cutoff is similar to the demarcation point for impairment in Mild Cognitive Impairment (Petersen et al., 1999) , the proposed middle ground between normal aging and dementia. A lower threshold for delayed recall might be needed because this is such a critical component of AD. When reviewing the predictive powers of the RBANS in Table 3 , there are also varying options for optimizing case classification. Some subtests of the RBANS (e.g., List Learning) yielded greater positive and negative predictive powers as the cutoff increases from −1 to −2 standard deviations. Other subtests (e.g., Semantic Fluency) seem to be optimized at −1.5 standard deviations. Clinicians and practitioners should consider the base rates of AD in their local populations when applying these test classification statistics (Labarge, McCaffrey, & Brown, 2003) .
There are several important study limitations. First, the RBANS scores are not completely independent of AD diagnosis because the scores were part of the information considered by a consensus team making clinical decisions. Although this is not an ideal situation, it should be reiterated that a consensus team making diagnoses also considered clinical history, imaging and other lab results, and multiple other clinical measures. These non-RBANS pieces of clinical information were supportive of the diagnosis of AD (e.g., gradually progressive onset, unremarkable lab results, mean CDR box scores in the mild to moderate dementia range, mean Mini Mental Status Examination = 22.4, mean Wechsler Memory Scale-III Logical Memory II = 1st percentile). A second limitation is that all AD cases were considered possible or probable, as no pathological confirmation of AD was available. The current AD sample's dementia severity ranged from mild to severe based on CDR sum of box scores, and additional research is needed to determine the utility of the RBANS with only mild and/or moderate AD severity or Mild Cognitive Impairment (Petersen et al., 1999) . Lastly, the RBANS was the only measure used to assess the cognition of the comparison patients, and some of these individuals might have had some mild levels of cognitive impairments. Two comments are relevant to this point. First, the mean scores on the RBANS for the comparison group were clearly in the average range (e.g., RBANS Total = 48th percentile) and not suggestive of cognitive impairments. Second, if patients with preclinical or early AD were included in the OKLAHOMA sample, this would serve to pull down the non-AD comparison RBANS scores, which would decrease the differences between samples, lower the estimates of diagnostic accuracy, and underestimate the true diagnostic utility of the RBANS in detecting cognitive deficits associated with AD. Nonetheless, future studies should strive to collect patient and control samples from the same pools.
Even with these limitations, results of the current study provide clinicians and researchers with evidence of the clinical utility of the RBANS in the evaluation of patients with suspected AD. It should be noted, however, that the RBANS, like any other neuropsychological measure, is not diagnostic of AD, but merely provides evidence of cognitive impairment that might be used to fulfill one or more criteria for a diagnosis. Future studies might expand this research by (1) investigating cognitive patterns on the RBANS in different types of dementia to aid with differential diagnosis, (2) examining longitudinal data to determine the clinical sensitivity of assessing change in patients with AD on the RBANS, (3) identifying the clinical utility of RBANS scores in detecting Mild Cognitive Impairment and very early Alzheimer's disease for recruitment into pharmaceutical trials of drugs designed to slow or prevent conversion from Mild Cognitive Impairment to AD or slow progression from mild to more severe AD, and (4) investigating the utility of RBANS scores in pharmacogenetic studies that aim to identify particular subgroups of AD patients (genetic or cognitive) that might benefit most from drug therapies. In conclusion, the present findings support the clinical usefulness of the RBANS in separating patients diagnosed with AD from comparison patients, with the Immediate and Delayed Memory Indexes of the RBANS being particularly sensitive targets for future investigations.
